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ndocannabinoid Inhibition
New Cardioprotective Strategy
gainst Doxorubicin Cardiotoxicity*
iovanni Fajardo, MD, Daniel Bernstein, MD
tanford, California
t has been almost 40 years since the quinone-containing
nthracycline doxorubicin was first isolated from cultures of
treptomyces peucetius var. caesius (1), and it remains one of
he most effective and commonly used drugs for treatment
f a variety of solid and hematologic malignancies. There is
strong correlation between total dose and antitumor
fficacy; however, soon after its discovery a second effect
ecame evident: patients treated with doxorubicin devel-
ped cardiomyopathic changes. This serious side effect has
ignificantly limited its potential clinical utility (2). Initial
eports documented the highest risk for doses above 450
g/m2 (3). However, with improved methods of detecting
ubtle changes in cardiac function, (e.g., alterations in left
entricular wall stress [4]), the incidence of doxorubicin
ardiotoxicity is now appreciated to be much higher than
reviously suspected. Alterations in wall stress have been
ocumented in 65% of long-term survivors of childhood
ancer, even at doses as low as 228 mg/m2 (5).
See page 528
It was initially believed that most anthracycline cardio-
yopathies developed late after therapy; however, there is
ncreasing recognition that acute injury plays an important
ole in chronic doxorubicin cardiomyopathy. Recent studies,
sing sensitive echocardiographic indexes rather than symp-
oms, show that 90% of children manifest some abnormality
n cardiac function during their first year of doxorubicin
herapy (6). These data suggest that patients develop sub-
linical cardiotoxicity rather than true “latency” between
rug exposure and onset of symptoms (5).
Despite much research, the cardiotoxicity associated with
oxorubicin remains a challenge. There have been impor-
ant advancements in understanding the basic mechanisms
nvolved in its cardiotoxic effects, in making an early
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.w
From the Division of Pediatric Cardiology, Department of Pediatrics, Stanford
niversity, Stanford, California.iagnosis using sensitive indexes of left ventricular perfor-
ance, and in developing more effective surveillance strat-
gies for those receiving the drug. A diverse array of
herapeutic strategies has emerged; however, new avenues of
esearch involving potential novel mechanisms may provide
lternative pathways by which to mitigate the cardiotoxicity.
Fortunately, the mechanism of doxorubicin’s toxicity in
ancer cells is thought to be different from its toxicity in
yocardial cells. There are several modes by which doxo-
ubicin induces cell damage: interference with DNA syn-
hesis, interference with DNA helicase activity, inhibition
f topoisomerase II, DNA adduct formation and cross-
inking, generation of free radicals, direct membrane effects,
nd the induction of apoptosis. The direct effects of doxo-
ubicin on DNA are thought to mediate its antitumor
oxicity (7), whereas the generation of free radicals and
embrane effects are thought to mediate its cardiotoxicity.
oxorubicin can also generate free radicals in cancer cells;
owever, this probably occurs only at supratherapeutic drug
oncentrations (8,9). That cardiomyocytes may be particu-
arly susceptible to doxorubicin’s free radical effects may be
artially explained by data showing that cardiomyocytes
ave low levels of catalase activity (10), that myocardial
lutathione peroxidase decreases after doxorubicin admin-
stration (11), and that doxorubicin undergoes redox cycling
n mitochondria, increasing the generation of free radicals.
he high volume fraction of mitochondria in the heart may
hus be linked to its vulnerability, because mitochondria are
ne of the major targets of doxorubicin’s toxicity (12–15).
dditional differences between the response of cancer versus
yocardial cells to doxorubicin may be explained by signal-
ng pathways that play opposing roles depending on the cell
ype in which they are acting; for example, in myocytes
oxorubicin-induced activation of nuclear factor-kappa B is
roapoptotic, whereas in cancer cells nuclear factor-kappa B
s antiapoptotic. Similarly, in myocytes activation of jun
-terminal kinase, signaling through activating transcription
actor-3, is antiapoptotic, whereas in cancer cells jun
-terminal kinase, signaling through AP1, is proapoptotic (9).
After the initial injury, several additional mechanisms
ave been implicated in the progression of doxorubicin
ardiotoxicity, including the dysregulation of iron
omeostasis (16), changes in intracellular Ca2, alter-
tions in mitochondrial respiratory chain function (17,
8), alterations in beta-adrenergic receptor signaling
19,20), differential activation of various mitogen-
ctivated protein kinase family members (21), alterations
n AKT signaling (22), alterations in Na-K adenosine
riphosphatase and Ca2 adenosine triphosphatase, and
mbalance in intracellular electrolytes (23). This growing
ist emphasizes the complex and multifaceted pathophys-
ology of doxorubicin cardiotoxicity, but also suggests
hat doxorubicin cardiomyopathy is an excellent model in
hich to study cellular crosstalk pathways involved in
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f cardiac disease.
In this issue of the Journal, Mukhopadhyay et al. (24)
resent evidence for the role of endocannabinoid system
nhibition in the protection against doxorubicin cardiotox-
city. The endocannabinoid system is a complex signaling
athway that includes endogenous cannabinoid ligands,
heir receptors, and several proteins implicated in their
ynthesis, release, transport, and degradation. In addition to
ts actions in the control of several central nervous system
unctions, the endocannabinoid system plays a role in
ardiovascular and metabolic regulation and has been linked
o obesity and cardiometabolic risk (25,26). Cannabinoid
eceptors are members of the transmembrane G protein-
oupled receptor superfamily, and the cloning of 2 receptors,
B1 and CB2, has been reported, although there may be
dditional subtypes (27,28). The CB1 receptors are abun-
ant in the brain but are also present at much lower
oncentrations in a variety of tissues, whereas CB2 receptors
re expressed primarily in the immune and hematopoietic
ystems (27). Mukhopadhyay et al. (24) report the efficacy
f the CB1 antagonists rimonabant or AM281 in protecting
gainst the cardiotoxicity induced 5 days after treatment
ith a single high dose of doxorubicin. In control mice,
P/dt, stroke work, ejection fraction, cardiac output, and
he load-independent end-systolic pressure volume relation-
hip index Emax were all decreased and left ventricular
nd-diastolic pressure was increased. These measures of
ardiotoxicity were all attenuated in mice pretreated with
ither CB1 antagonist (but not with CB2 antagonists). In
itro, the toxicity of doxorubicin in H9c2 cells was also
revented by CB1 antagonists. Finally, anandamide, a nat-
ral ligand of the CB1 receptor, was elevated in the
yocardium after doxorubicin administration, suggesting
ctivation of the endocannabinoid system.
These data provide support for the role of the endocan-
abinoid system as a potentially novel target for the protec-
ion against doxorubicin cardiotoxity. Unfortunately, the
resent study does not provide sufficient data to fully
nderstand the mechanism for the beneficial effects of CB1
nhibition. Further investigation of the signaling pathways
ssociated with endocannabinoid/doxorubicin interaction
ill be required as well as studies to determine whether
nhibition of CB1 receptors has an effect on the antitumor
fficacy of doxorubicin. Additional CB1 and CB2 agonists
nd antagonists as well as the use of CB1 knockout mice
29,30) will be useful tools in confirming the current results
nd placing these in a mechanistic framework. Finally,
ecause there may be mechanistic differences between acute
ersus chronic doxorubicin cardiotoxicity, studies using CB1
ntagonists during chronic administration of a lower dose of
oxorubicin will be important. Developing a better under-
tanding of the role of this novel receptor system in
ediating cardioprotection may have benefits that extend
eyond doxorubicin cardiotoxicity to other forms of cardiac
njury.eprint requests and correspondence: Dr. Daniel Bernstein,
epartment of Pediatrics, Stanford University, 750 Welch Road,
uite 305, Palo Alto, California 94304. E-mail: danb@
tanford.edu.
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